Novel technologies for oral delivery of poorly soluble drugs

Research Journal of Pharmaceutical, Biological and Chemical Sciences

Volumn 1, Issue 4, 2010, Pages 292-305

  Sharma, Suchika ^a   Aggarwal, Geeta ^a  

^a Rayat Institute of Pharmacy   (India)

Author keywords

Nanocrystal; Poorly soluble drugs; Sono crystallisation; Supercritical fluid

Indexed keywords

ACETYLSALICYLIC ACID; AMPHOTERICIN B; APREPITANT; BETA CYCLODEXTRIN; CELLULOSE; CYCLODEXTRIN; DANAZOL; DNA VACCINE; EXCIPIENT; FLURBIPROFEN; GELATIN; GRISEOFULVIN; IBUPROFEN; LIPID; MACROGOL; NANOCRYSTAL; NANOPARTICLE; NAPROXEN; PACLITAXEL; PEPTIDE DERIVATIVE; PHOSPHOLIPID; POLYMER; POVIDONE; PROTEIN; RAPAMYCIN; SOLID LIPID NANOPARTICLE; SOLVENT; SURFACTANT; UNINDEXED DRUG; WATER;

ARTICLE; CHEMICAL MODIFICATION; CONTROLLED RELEASE FORMULATION; CRYSTALLIZATION; DISPERSION; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG STABILITY; HYDROPHOBICITY; IMMUNOCYTOCHEMISTRY; MICROEMULSION; MISCIBILITY; NANOEMULSION; NANOTECHNOLOGY; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; PH; SPRAY DRYING; SUPERCRITICAL FLUID;

EID: 79952521274     PISSN: None     EISSN: 09758585     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Speiser PP. Medpharm Stuttgart: Scientific Publishers; 1998:15-28.
2. Merisko-Liversidge E. Orlando, Florida; 2002:20-23.
3. Junghanus J-UAH, Müller RH. Int J Nanomedicines (Dovepress). 2008; 3(3):295-310.
4. Tufts Center for the Study of Drug Development; 2003.
5. Ellul S, Director, Business, Eurand, Inc., Int. Pharm. 2007.
6. Hite M, Pharmaceutical Manufactursing and Packing Sourcer Summer '03 issue. Samedan Ltd 2003.
7. Banga S, Chawla G, Bansal AK. Pharmagenerics 2004:70-74.
8. Crystallization process using ultrasound, United States Patent 20020031577.
9. El-Kamel AH. Wiley Interscience 2008; 69 (1):34-41.
10. Pasquali I, Bettini R, Giordano F. Eur J Pharm sci 2006; 27: 299-310.
11. Shinde A J. Pharma Info net. 2007; 5(6).
12. Kakumanu VK, Bansal AK. Pharmaceutical Research, Businessbriefing: Labtech, 2004: 71 73.
13. Türk M, Hils P, Helfgen B, Schaber K, Martin HJ, Wahl MA. J Supercrit Fluids 2002:75-84.
14. Pathak P, Meziani MJ, Desai T, Sun YP. J Am Chem Soc 2004; 126 (35): 10842-10843.
15. Prajapati BG, Patel RP, Patel RB, Patel GN, Patel HR, Patel M. www.pharmaquality.com.
16. Porta G D, Vittori CD, Reverchon E. AAPS Pharm SciTech 2005; 06(03): E421-E428.
17. Ran Y, Jain A, Yalkowsky SH. J Pharm Sci 2005; 94(2): 297-303.
18. Nunez FAA and Yalkowsky SH. J Pharm Sci Technol 1998; 52(1): 33-36.
19. Han SK, Kim GY, Park YH. Drug Dev Ind Pharm 1999; 25(11):1193-1197.
20. Loftsson T, Brewster ME. J Pharm Sci 1996; 85 (10):1017-1025.
21. Chang R K, Shojaei A H. Drug Dev Ind Pharm 2004; 30 (3):297-302.
22. Serajuddin AT. J Pharm Sci 1999; 88 (10):1058-1066.
23. Leuner C, Dressman J. Eur J Pharm BioPharm 2000; 50 (1): 47-60.
24. Breitenbach J. Eur J Pharm BioPharm 2002; 54 (2):107-117.
25. Lipinski C. Am Pharm Rev 2002; 5: 82-85.
26. Muller RH, Bohm BHL. Medpharm Scientific Publishers, Stuttgart, Germany 1998:149-174.
27. Muller RH, Jacobs C, Kayser O. Adv Drug Deliv Rev 2001; 47 (1): 3-19.
28. Liversidge EM, Liversidge GG, Cooper ER. Eur J Pharm Sci 2003; 18 (2): 113-120.
29. Lockman PR, Mumper RJ, Khan MA, Allen DD. Drug Dev Ind Pharm 2002; 28 (1): 1-13.
30. Rabinow BE. Nat Rev Drug Discov 2004; 3 (9): 785-796.
31. Patravale VB, Date AA, Kulkarni RM. J Pharm Pharmacol 2004; 56 (7): 827-840.
32. Peters K, Leitzke S, Diederichs JE, Borner K, Hahn H, Müller RH, Ehlers S. J Antimicrob Chemother 2000; 45 (1): 77-83.
33. Moghimi SM, Hunter AC, Murray JC. Pharmacol Rev 2001; 53 (2): 283-318.
34. Vergote GJ, Vervaet C, Van Driessche I, Hoste S, De Smedt S, Demeester J, Jain RA, Ruddy S, Remon JP. Int J Pharm 2001; 219 (1-2): 81-87.
35. Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. Eur J Pharm Sci 2002; 16 (1-2): 3-61.
36. Kipp JE. Int J Pharm 2004; 284 (1-2): 109-122.
37. Kirupakar BR. Express Pharma Pulse.htm, http://www.expresspharmapulse.com.
38. Trotta M, Gallarate M, Pattarino F, Morel S et al. J. Controlled Release 2001; 76 (1-2): 119-128.
39. Trotta M, Gallarate M, Carlotti ME, Morel S. Int J Pharm 2003; 254(2): 235-242.
40. Shah P, Bhalodia D, Shelat P. Systemic review in pharmacy 2010; 1(1): 24-32.
41. Rosano HL, Cavello JL, Lyons GB. 1987:259-257.
42. Tiwari SB, Shenoy DB, Amiji MM. 9th Annual NSTI Nanotechnology conference and trade show-nanotech 2006.
43. Shakeel F, Faisal MS. Pharmaceutical development and technology 2009 informahealthcare.com.
44. Williams RO, Johnston KP, Young TJ, Rogers TL, Barron MK, Yu Z, Hu J H. US Patent 6,862,890 (2005).
45. Rogers TL, Hu J, Yu Z, Johnston KP, Williams RO 3rd. Int J Pharm 2002; 242 (1-2): 93-100.
46. Rogers TL, Nelsen AC, Hu J, Brown JN, Sarkari M, Young TJ, Johnston KP, Williams RO 3rd. Eur J Pharm BioPhar.2002; 54 (3): 271-280.
47. Rogers TL, Nelsen AC, Sarkari M, Young TJ, Johnston KP, Williams RO 3rd. Pharm Res 2003; 20 (3): 485-493.
48. Hu J, Johnston KP, Williams RO. Eur J Pharm Sci 2003; 20 (3): 295-303.
49. Hu J, Johnston KP, Williams RO 3rd. Int J Pharm 2004; 271 (1-2): 145-154.
50. Hu J, Johnston KP, Williams RO3rd. Drug Dev. Ind. Pharm. 2004; 30 (7): 695-704.
51. Rogers TL, Nelsen AC, Sarkari M. Pharm Res 2003.
52. Radtke M. New Drugs 2001; 3: 62-68.
53. Mazzola L. Nat Biotechnol 2003; 10: 1137-1143.
54. Kondo N, Iwao T, Masuda H, Yamanouchi K, Ishihara Y, Yamada N, Haga T, Ogawa Y, Yokoyama K. Chem Pharm Bull 1993; 41: 737-740.
55. Müller RH, Möschwitzer JP. 2005 DE 10 2005 053 862.2 application.
56. NanoMorph technology for Amorphous Nanoparticles, www.soliqs.com.
57. Kipp JE, TakWong JC, Doty MJ, Rebbeck CL. 2002 US Pat. application no. 20020168402 A1.
58. Radke M. www.pharmasol-berlin.de.
59. http://www.crititech.com/technology.html.
60. Delmas G, Chen WC, Tan F, Kashiwazaki R, Zarif L, Perlin DS. Antimicrobial Agents and Chemotherapy 2002; 46: 2704-2707.
61. http://EzineArticles.com/?expert=Marcia_Henin.
62. http://www.physicapharma.com/.